Skip to main content

Table 3 Change in tumor size on MRI after a 6-week biologic window for patients on standard treatment

From: A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

Response

N

Mean shrinkage (cm)

Std. dev

Minimum (cm)

Maximum (cm)

No

6

− 0.13

0.45

− 1.0

0.3

Yes

5

2.58

1.88

0.2

4.9

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us